Latest news with #DawahPharma
Zawya
3 days ago
- Business
- Zawya
Egypt's HoldiPharma partners with US-based Dawah Pharma to manufacture, export to global markets
Arab Finance: The state-owned pharmaceutical firm HoldiPharma signed a partnership agreement with US-based Dawah Pharma to establish a joint venture for the manufacturing and export of pharmaceuticals and nutritional supplements to international markets, including North America and Europe, as per a statement. The agreement was signed in the presence of Prime Minister Mostafa Madbouly, who emphasized that the deal reflects international confidence in Egyptian industry and fulfills presidential directives to bolster national strategic sectors, particularly pharmaceuticals. Under the agreement, the newly formed joint venture, 60% owned by Dawah Pharma and 40% by the Egyptian side, will begin with the export of six nutritional supplement products already approved for the US market. Future plans include manufacturing and exporting a wide range of pharmaceutical products, such as ampoules, sterile injections, ophthalmic preparations, and over-the-counter medications. The venture will utilize advanced pharmaceutical manufacturing technologies, including syrups, tablets, prefilled syringes, and transdermal patches. The company will also operate under the regulatory frameworks of the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), ensuring compliance and boosting the global competitiveness of Egyptian pharmaceutical products. © 2020-2023 Arab Finance For Information Technology. All Rights Reserved. Provided by SyndiGate Media Inc. (
Zawya
3 days ago
- Business
- Zawya
Egypt, US partner to launch global pharmaceutical manufacturing, export venture
Egypt has signed a major joint venture agreement with US-based Dawah Pharma to manufacture and export pharmaceutical products and nutritional supplements to global markets, with a strategic focus on North America and Europe. The deal marks a significant milestone in Egypt's push to expand its pharmaceutical exports and attract foreign investment to its health sector. Prime Minister Mostafa Madbouly witnessed the signing ceremony, which took place in the presence of Deputy Prime Minister for Human Development and Minister of Health and Population Khaled Abdel Ghaffar, Minister of Public Enterprise Sector Mohamed El-Shimy, Head of the Egyptian Drug Authority Ali El-Ghamrawy, and Hisham Setit, Head of the Unified Procurement Authority for Medical Supplies and Technology. The agreement was signed by Ashraf El-Khouly, Executive Managing Director of the Egyptian Holding Company for Pharmaceuticals—affiliated with the Ministry of Public Enterprise Sector—and Hossam Abdel Maksoud, Chairman of Dawah Pharma. Prime Minister Madbouly said the agreement reflects Egypt's broader strategy to enhance national industries, with the pharmaceutical sector identified as a key priority. He described the partnership as a strong vote of confidence in the quality and potential of Egyptian manufacturing, particularly in the medical field. Minister El-Shimy emphasized that the partnership follows major investments to modernize the holding company's infrastructure, upgrade production lines, and align operations with international Good Manufacturing Practices (GMP). He described the venture as a pivotal step in Egypt's plan to boost pharmaceutical exports, strengthen international collaboration, and increase foreign direct investment. Under the agreement, the new joint venture will manufacture and export a wide range of products including ampoules, nutritional supplements, sterile injections, ophthalmic preparations, and over-the-counter (OTC) medications. The first phase will focus on exporting six pre-approved dietary supplements to the US market—an unprecedented move for the Holding Company for Pharmaceuticals, after meeting all relevant international regulatory and quality benchmarks. The venture will leverage state-of-the-art manufacturing technologies for a diverse range of dosage forms including syrups, tablets, ampoules, pre-filled syringes, and transdermal patches. This is expected to accelerate global market entry for Egyptian-made products and support long-term growth for the company and its subsidiaries. El-Shimy affirmed that the new company will comply with the most stringent international regulations, particularly those set by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), to ensure the competitiveness of Egyptian products in North America, Europe, and emerging markets in Africa and Asia. As per the terms of the agreement, the Egyptian Holding Company for Pharmaceuticals will hold a 40% stake in the joint venture, while Dawah Pharma will own 60%. The partnership will also spearhead efforts to open new international markets for Egyptian pharmaceutical exports, solidifying Egypt's position as a regional hub for high-quality medical manufacturing. © 2024 Daily News Egypt. Provided by SyndiGate Media Inc. (
Daily News Egypt
4 days ago
- Business
- Daily News Egypt
Egypt, US partner to launch global pharmaceutical manufacturing, export venture
Egypt has signed a major joint venture agreement with US-based Dawah Pharma to manufacture and export pharmaceutical products and nutritional supplements to global markets, with a strategic focus on North America and Europe. The deal marks a significant milestone in Egypt's push to expand its pharmaceutical exports and attract foreign investment to its health sector. Prime Minister Mostafa Madbouly witnessed the signing ceremony, which took place in the presence of Deputy Prime Minister for Human Development and Minister of Health and Population Khaled Abdel Ghaffar, Minister of Public Enterprise Sector Mohamed El-Shimy, Head of the Egyptian Drug Authority Ali El-Ghamrawy, and Hisham Setit, Head of the Unified Procurement Authority for Medical Supplies and Technology. The agreement was signed by Ashraf El-Khouly, Executive Managing Director of the Egyptian Holding Company for Pharmaceuticals—affiliated with the Ministry of Public Enterprise Sector—and Hossam Abdel Maksoud, Chairman of Dawah Pharma. Prime Minister Madbouly said the agreement reflects Egypt's broader strategy to enhance national industries, with the pharmaceutical sector identified as a key priority. He described the partnership as a strong vote of confidence in the quality and potential of Egyptian manufacturing, particularly in the medical field. Minister El-Shimy emphasized that the partnership follows major investments to modernize the holding company's infrastructure, upgrade production lines, and align operations with international Good Manufacturing Practices (GMP). He described the venture as a pivotal step in Egypt's plan to boost pharmaceutical exports, strengthen international collaboration, and increase foreign direct investment. Under the agreement, the new joint venture will manufacture and export a wide range of products including ampoules, nutritional supplements, sterile injections, ophthalmic preparations, and over-the-counter (OTC) medications. The first phase will focus on exporting six pre-approved dietary supplements to the US market—an unprecedented move for the Holding Company for Pharmaceuticals, after meeting all relevant international regulatory and quality benchmarks. The venture will leverage state-of-the-art manufacturing technologies for a diverse range of dosage forms including syrups, tablets, ampoules, pre-filled syringes, and transdermal patches. This is expected to accelerate global market entry for Egyptian-made products and support long-term growth for the company and its subsidiaries. El-Shimy affirmed that the new company will comply with the most stringent international regulations, particularly those set by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), to ensure the competitiveness of Egyptian products in North America, Europe, and emerging markets in Africa and Asia. As per the terms of the agreement, the Egyptian Holding Company for Pharmaceuticals will hold a 40% stake in the joint venture, while Dawah Pharma will own 60%. The partnership will also spearhead efforts to open new international markets for Egyptian pharmaceutical exports, solidifying Egypt's position as a regional hub for high-quality medical manufacturing.
Egypt Today
4 days ago
- Business
- Egypt Today
Egypt & U.S. Form Joint Venture to Boost Global Pharmaceutical Exports
CAIRO - 28 May 2025: The Holding Company for Pharmaceuticals, Chemicals, and Medical Supplies has entered into a strategic joint venture with American pharmaceutical firm Dawah Pharma. This partnership marks a significant step in Egypt's push to expand its pharmaceutical footprint globally, with plans to manufacture and export a broad range of pharmaceutical products and dietary supplements to international markets. Minister of Public Business Sector Mohamed Shimi announced that the new venture will produce a diverse portfolio of products, including ampoules, sterile injections, ophthalmic solutions, over-the-counter (OTC) medications, and dietary supplements. The joint venture structure grants the Egyptian side a 40 percent share, while Dawah Pharma holds a 60% majority stake. The newly formed company will focus primarily on exporting its products and opening new channels in global markets. In a milestone move, the partnership's first phase will see the manufacture and export of six specific dietary supplements to the United States—marking the first time in the Holding Company's history to achieve such a feat after meeting rigorous international standards and requirements. The agreement also leverages advanced pharmaceutical manufacturing technologies, including the production of syrups, tablets, ampoules, pre-filled syringes, and transdermal patches. These innovations are expected to significantly accelerate product deployment and support long-term growth for the Holding Company and its subsidiaries. Shimi stressed that the new company will strictly follow international regulatory standards, particularly those enforced by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Adhering to these benchmarks will boost the global competitiveness of Egyptian pharmaceuticals—not only in the high-demand markets of Europe and North America but also in emerging markets across Africa and Asia.
